Skip to main content
ZEOX
OTC Life Sciences

Wendy Grey and Greyt Ventures tighten grip on Zeo ScientifiX with 23.88% stake and 49.38% voting power

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.65
Mkt Cap
$12.932M
52W Low
$1.2
52W High
$2.99
52W Position info
38% above low
Off High info
45% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

ZEOX sits 38% above its 52-week low of $1.2 on light trading volume (0.2× avg).

Summary

New equity grants have raised Wendy Grey and Greyt Ventures, LLC's beneficial ownership in Zeo ScientifiX to 23.88% of common stock and total voting power to 49.38%.


Key Events · Ownership and Investor Activity · ZEOX

  • Ownership Stake Increased

    Beneficial ownership of common stock now stands at 2,117,500 shares, or 23.88% of the class, for Wendy Grey and Greyt Ventures, LLC — an increase driven by fresh equity grants.

  • Voting Power Nears Majority

    When combined with 50 shares of Series C Preferred Stock, which carry 25.5% voting power, the reporting persons control 49.38% of total voting power.

  • New Equity Grants

    The boost reflects 625,000 stock options granted on June 10, 2026, and 87,500 restricted shares granted on January 14, 2026, that vest on July 14, 2026 — both issued under the 2021 Equity Incentive Plan.

  • No Immediate Plans for Further Changes

    The filing indicates no definite plans to acquire or dispose of additional shares, though future equity awards under incentive plans remain possible.


Analysis · ZEOX · Life Sciences

Nearly half of Zeo ScientifiX's voting power now rests with Wendy Grey and Greyt Ventures, LLC, following the grant of 625,000 stock options and 87,500 restricted shares. Awarded under the company's equity incentive plan, the new equity lifts their beneficial ownership to 23.88% of common stock and, together with Series C Preferred Stock, pushes total voting power to 49.38%. The consolidation arrives as operational momentum builds — monthly sales recently crossed $1 million and Q2 2026 revenue surged 124.6%.

At the time of this filing, ZEOX was trading at $1.65 on OTC in the Life Sciences sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $1.20 to $2.99. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZEOX - Latest Insights

ZEOX
Jun 15, 2026, 4:21 PM EDT
Source: Wiseek News
Importance Score:
9
ZEOX
Jun 15, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
ZEOX
Jun 12, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
9
ZEOX
Jun 09, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
ZEOX
May 27, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
7